Inactive/Delisted stock

Qualigen Therapeutics Stock (NASDAQ:QLGN)


Chart

Previous Close

$1.83

52W Range

$1.61 - $10.50

50D Avg

$2.84

200D Avg

$3.53

Market Cap

$3.04M

Avg Vol (3M)

$850.87K

Beta

-0.17

Div Yield

-

QLGN Company Profile


Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Jun 23, 2015

Website

QLGN Performance


Latest Earnings Call Transcripts


Q1 21Aug 18, 20 | 5:00 PM

Peer Comparison


TickerCompany
ARTLArtelo Biosciences, Inc.
ATHEAlterity Therapeutics Limited
SONNSonnet BioTherapeutics Holdings, Inc.
TickerGate Footer Logo

Tickergate is an advanced stock research & comparison platform for informed data-driven investment decisions. 100% customizable, institutional-grade data, easy to use.

Company

AboutContact

Connect

LinkedIn

©2025 Tickergate

Tickergate does not provide financial advices and does not issue recommendations or offers to buy stocks of sell any securities. Information is provided 'as-is' and solely for informational purposes as an advice. Tickergate does not bear any responsibility or any losses or damages that may occur as a result of reliance on this data.
Start a conversation

Ask me anything about stocks, markets, or financial data.

Market Trends
Compare Stocks